Unicycive Therapeutics, Inc
  • About
    • Our Story
    • Our Focus
    • Our Team
    • Board of Directors
  • Our Science
    • Our Approach
    • Pipeline
    • Oxylanthanum Carbonate (OLC)
    • UNI-494
    • Publications & Press
  • Investors
  • Contact
    • Careers

News

Investors

Investors

  • Overview
  • News
  • Events & Presentations
    • IR Calendar
    • Presentations
  • Governance
    • Overview
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Financial Results
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • Contacts
    • FAQ
    • Email Alerts
Mar 04, 2024 7:03am EST

Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients

Feb 14, 2024 7:03am EST

Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting

Jan 29, 2024 7:03am EST

Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference

Jan 23, 2024 7:03am EST

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Dec 18, 2023 7:03am EST

Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis

Nov 29, 2023 7:03am EST

Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023

Nov 14, 2023 4:15pm EST

Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update

Oct 23, 2023 7:03am EDT

Unicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)

Sep 06, 2023 7:03am EDT

Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD

Aug 29, 2023 7:03am EDT

Unicycive Therapeutics Featured on Nasdaq Amplify Issuer Spotlight Series

  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
Unicycive Theraputics, Inc

About
Our story
Our focus
Our team
Boards of Directors

Our Science
Our Approach
Therapeutic Pipeline
OLC
UNI-494
Publications & Press

Investors

Contact
Careers

4300 El Camino Real, Suite #210
Los Altos, CA 94022
+1 (650) 351-4495
info@unicycive.com

  • LinkedIn
  • YouTube
  • Facebook
  • Instagram
  • Twitter

Copyright © 2025 Unicycive

Legal Notices and Terms of Use Privacy Policy Ad and Cookie Policy